New collaboration between Eye2Gene and Heidelberg Engineering announced at ARVO 2024

Eye2Gene is a research project funded by the National Institute for Health and Care Research (NIHR), based at UCL Institute of Ophthalmology and Moorfields Eye Hospital. Its aim is to develop artificial intelligence that can predict (from images acquired using the Heidelberg retinal scanner) which type of inherited retinal disease the patient has, and specifically which gene is likely to be affected. Once validated, Eye2Gene can help make decisions about patient care.

Heidelberg Engineering is a global leader in ophthalmic imaging and data technologies which is widely used by eye care specialists working on inherited retinal diseases.

The two organisations just announced their collaborative partnership at the ARVO 2024 Annual Meeting in Seattle.  Eye2Gene lead, UCL Institute of Ophthalmology Population and Data Sciences Deputy Theme lead, Dr Nikolas Pontikos said:

Given that our Eye2Gene AI has been trained on Heidelberg imaging, this represents a significant step forward in the product development pathway of the Eye2Gene medical technology. We hope to leverage this exciting opportunity to accelerate the validation and piloting of our technology within the NHS and internationally with real-world evidence, so that eventually more people affected by inherited retinal diseases will receive a genetic diagnosis and the care they need.“Given that our Eye2Gene AI has been trained on Heidelberg imaging, this represents a significant step forward in the product development pathway of the Eye2Gene medical technology.  We hope to leverage this exciting opportunity to accelerate the validation and piloting of our technology within the NHS and internationally with real-world evidence, so that eventually more people affected by inherited retinal diseases will receive a genetic diagnosis and the care they need.Given that our Eye2Gene AI has been trained on Heidelberg imaging, this represents a significant step forward in the product development pathway of the Eye2Gene medical technology.  We hope to leverage this exciting opportunity to accelerate the validation and piloting of our technology within the NHS and internationally with real-world evidence, so that eventually more people affected by inherited retinal diseases will receive a genetic diagnosis and the care they need.

Links

• Dr Nikolas Pontikos 
• Eye2Gene
• Heidelberg Engineering 
• Article on Businesswire
• Population and Data Science at the IoO